サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：希少内分泌疾患治療の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 適応症別、薬剤タイプ別、投与モード別、流通チャネル別、地域別
市場調査レポート
商品コード
1410592

希少内分泌疾患治療の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 適応症別、薬剤タイプ別、投与モード別、流通チャネル別、地域別

Rare Endocrine Disease Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:
出版日: | 発行: Fairfield Market Research | ページ情報: 英文 170 Pages | 納期: 2～5営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
希少内分泌疾患治療の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 適応症別、薬剤タイプ別、投与モード別、流通チャネル別、地域別
出版日: 2024年01月10日
発行: Fairfield Market Research
ページ情報: 英文 170 Pages
納期: 2～5営業日
  • 全表示
  • 概要
  • 目次
概要

今や世界の大流行と考えられている肥満は、多嚢胞性卵巣症候群や甲状腺機能低下症のような一般的な疾患だけでなく、視床下部障害やクッシング症候群のようなまれな疾患も含め、さまざまな内分泌疾患と密接に関連しています。

肥満発症の基礎にあるメカニズムは、特定の内分泌疾患によって異なります。まれな内分泌疾患の場合、成長ホルモンや甲状腺機能との相互作用が極めて重要であり、多くの場合、脂肪新生や脂肪細胞分化の亢進と結びついています。

世界中の研究者が、特に太りすぎの患者に重点を置いて、希少内分泌疾患の治療戦略の評価に積極的に取り組んでいます。例えば、ニューカッスル大学の科学者たちは、様々な病因因子を考慮しながら、肥満発症の自然史を熱心に評価しています。

包括的な評価はまだ達成されていませんが、研究者たちは、評価プロセスを拡大し、一般的な内分泌学的原因を除外し、適切な治療法を選択する道を開くために、臨床検査や身体検査を実施しています。

内分泌疾患は希少であるため、研究者や臨床医にとって、確実な臨床試験のための十分な患者データの収集が課題となっています。Endocrine Genomics Virtual Laboratory（endoVL）は、分析ツールや広範なデータセットへの安全なオンラインアクセスを提供することで、この課題に対処し、希少内分泌疾患の診断と治療を前進させる共同研究を可能にします。

8,500例以上の副腎腫瘍が登録されているendoVLは、研究者が大規模コホートを活用して統計学的に有意な解析を行うことを可能にします。現在、endoVLでは25以上の大規模臨床試験が進行中であり、世界中の研究グループが参加しています。このような共同研究の努力は、世界の希少内分泌疾患治療市場における新たな成長機会を解き放つ大きな可能性を秘めています。

希少内分泌疾患は多くの場合、多臓器症状を呈し、明確な病態生理学的障害によって最初に眼に現れます。希少内分泌疾患の眼症状を認識することは、迅速な診断、治療、重大な罹患率や死亡率の予防に極めて重要です。

バイオテクノロジー企業や製薬企業は、医学研究者とともに、希少内分泌疾患の眼科的症状への対応に注力し、この重要な分野における治療開発と技術革新を促進することが期待されます。

当レポートでは、世界の希少内分泌疾患治療市場について調査し、市場の概要とともに、適応症別、薬剤タイプ別、投与モード別、流通チャネル別、地域別動向、および市場に参入する企業の競合動向などを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の定義とセグメンテーション
  • 市場力学
  • バリューチェーン分析
  • ポーターのファイブフォース分析
  • COVID-19の影響分析
  • ウクライナとロシアの紛争の影響
  • 経済概要
  • PESTLE分析

第3章 世界の希少内分泌疾患治療市場の見通し、2018年～2031年

  • 世界の希少内分泌疾患治療市場の見通し、適応症別、金額（100万米ドル）、数量（トン）、2018年～2031年
  • 世界の希少内分泌疾患治療市場の見通し、薬剤タイプ別、金額（100万米ドル）、数量（トン）、2018年～2031年
  • 世界の希少内分泌疾患治療市場の見通し、投与モード別、金額（100万米ドル）、数量（トン）、2018年～2031年
  • 世界の希少内分泌疾患治療市場の見通し、流通チャネル別、金額（100万米ドル）、数量（トン）、2018年～2031年
  • 世界の希少内分泌疾患治療市場の見通し、地域別、金額（100万米ドル）、数量（トン）、2018年～2031年

第4章 北米の希少内分泌疾患治療市場の見通し、2018年～2031年

第5章 欧州の希少内分泌疾患治療市場の見通し、2018年～2031年

第6章 アジア太平洋の希少内分泌疾患治療市場の見通し、2018年～2031年

第7章 ラテンアメリカの希少内分泌疾患治療市場の見通し、2018年～2031年

第8章 中東・アフリカの希少内分泌疾患治療市場の見通し、2018年～2031年

第9章 競合情勢

  • 投与モード別と薬剤タイプ別のヒートマップ
  • メーカーと薬剤タイプ別のヒートマップ
  • 企業の市場シェア分析、2023年
  • 競争力ダッシュボード
  • 企業プロファイル
    • Novartis
    • Ipsen
    • Pfizer, Inc
    • Teva
    • EMD serono
    • Novo Nordisk
    • Eli Lilly
    • Shire
    • Amgen, Inc
    • Corcept Therapeutics
    • Novelion Therapeutics

第10章 付録

目次

The global rare endocrine disease treatment market, intricately linked with obesity and endocrine disorders, is poised for moderate growth in the forecast period from 2024 to 2031, according to a recent research study conducted by Fairfield Market Research.

Endocrine Diseases and the Obesity Connection

Obesity, now considered a global pandemic, has been closely associated with a range of endocrine diseases, including both common conditions like polycystic ovarian syndrome and hypothyroidism, as well as rare ailments such as hypothalamic disorders and Cushing's syndrome.

The mechanisms underlying obesity development vary depending on the specific endocrine disorder. In the case of rare endocrine diseases, interactions with growth hormones and thyroid functions are pivotal, often coupled with increased adipogenesis and adipocyte differentiation.

Researchers Focus on Treatment Evaluation

Researchers worldwide are actively engaged in evaluating treatment strategies for rare endocrine diseases, with a particular emphasis on overweight patients. For instance, scientists at the University of Newcastle are diligently assessing the natural history of obesity development, taking into account the various etiological factors at play.

While a comprehensive evaluation has not yet been achieved, researchers are conducting laboratory tests and physical examinations to expand the evaluation process, ruling out common endocrine causes and paving the way for appropriate treatment selection.

Research Collaboration Revolutionizes Rare Endocrine Disease Treatment

The rarity of endocrine diseases poses challenges for researchers and clinicians in gathering sufficient patient data for robust clinical trials. The Endocrine Genomics Virtual Laboratory (endoVL) addresses this challenge by providing secure online access to analytical tools and extensive datasets, enabling collaborative efforts to advance the diagnosis and treatment of rare endocrine diseases.

With more than 8,500 registered cases of adrenal tumors, endoVL empowers researchers to leverage large cohorts for statistically significant analyses. Currently, more than 25 large-scale clinical trials are underway within endoVL, engaging research groups from around the world. This collaborative research effort holds immense potential to unlock new growth opportunities in the global rare endocrine disease treatment market.

Innovations in Ophthalmic Manifestations

Rare endocrine disorders often manifest multi-organ symptoms, initially appearing in the eyes through distinct pathophysiological disturbances. Recognizing ophthalmic manifestations of rare endocrine diseases is crucial for swift diagnosis, treatment, and the prevention of significant morbidity and mortality.

Biotechnology and pharmaceutical companies, alongside medical researchers, are expected to focus on addressing ophthalmic manifestations of rare endocrine diseases, fostering treatment developments and innovations in this critical area.

Key Players in Rare Endocrine Disease Treatment

Prominent companies contributing to advancements in rare endocrine disease treatment, as identified by PMR's report, include Novartis, Ipsen, Pfizer, Inc., Teva, EMD Serono, Novo Nordisk, Eli Lilly, Shire, Amgen, Inc., Corcept Therapeutics, and Novelion Therapeutics.

Notably, Spruce Biosciences, a clinical-stage biotechnology firm, recently received FDA orphan drug designation for its SPR001, a potential treatment for congenital adrenal hyperplasia (CAH), a rare endocrine disease.

Rare Endocrine Disease Treatment Market Segmentation

Indication

  • Acromegaly
  • Central Diabetes Insipidus
  • Ahumada-Del Castillo Syndrome
  • Hypoparathyroidism
  • Other Indications

Drug Type

  • Biologics
  • Organic Compounds

Mode of Administration

  • Injectables
  • Oral
  • Others

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region

  • North Americ
  • Latin America
  • Europe
  • Japan
  • APEJ
  • MEA

Table of Contents

1. Executive Summary

  • 1.1. Global Rare Endocrine Disease Treatment Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value and Volume, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Rare Endocrine Disease Treatment Market Outlook, 2018 - 2031

  • 3.1. Global Rare Endocrine Disease Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Acromegaly
      • 3.1.1.2. Central Diabetes Insipidus
      • 3.1.1.3. Ahumada-Del Castillo Syndrome
      • 3.1.1.4. Hypoparathyroidism
      • 3.1.1.5. Other Indications
  • 3.2. Global Rare Endocrine Disease Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Biologics
      • 3.2.1.2. Organic Compounds
  • 3.3. Global Rare Endocrine Disease Treatment Market Outlook, by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Injectables
      • 3.3.1.2. Oral
      • 3.3.1.3. Others
  • 3.4. Global Rare Endocrine Disease Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. Hospital Pharmacies
      • 3.4.1.2. Retail Pharmacies
      • 3.4.1.3. Online Pharmacies
  • 3.5. Global Rare Endocrine Disease Treatment Market Outlook, by Region, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 3.5.1. Key Highlights
      • 3.5.1.1. North America
      • 3.5.1.2. Europe
      • 3.5.1.3. Asia Pacific
      • 3.5.1.4. Latin America
      • 3.5.1.5. Middle East & Africa

4. North America Rare Endocrine Disease Treatment Market Outlook, 2018 - 2031

  • 4.1. North America Rare Endocrine Disease Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Acromegaly
      • 4.1.1.2. Central Diabetes Insipidus
      • 4.1.1.3. Ahumada-Del Castillo Syndrome
      • 4.1.1.4. Hypoparathyroidism
      • 4.1.1.5. Other Indications
  • 4.2. North America Rare Endocrine Disease Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Biologics
      • 4.2.1.2. Organic Compounds
  • 4.3. North America Rare Endocrine Disease Treatment Market Outlook, by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Injectables
      • 4.3.1.2. Oral
      • 4.3.1.3. Others
  • 4.4. North America Rare Endocrine Disease Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. Hospital Pharmacies
      • 4.4.1.2. Retail Pharmacies
      • 4.4.1.3. Online Pharmacies
  • 4.5. North America Rare Endocrine Disease Treatment Market Outlook, by Country, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 4.5.1. Key Highlights
      • 4.5.1.1. U.S. Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 4.5.1.2. U.S. Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 4.5.1.3. U.S. Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 4.5.1.4. U.S. Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 4.5.1.5. Canada Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 4.5.1.6. Canada Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 4.5.1.7. Canada Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 4.5.1.8. Canada Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 4.5.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Rare Endocrine Disease Treatment Market Outlook, 2018 - 2031

  • 5.1. Europe Rare Endocrine Disease Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Acromegaly
      • 5.1.1.2. Central Diabetes Insipidus
      • 5.1.1.3. Ahumada-Del Castillo Syndrome
      • 5.1.1.4. Hypoparathyroidism
      • 5.1.1.5. Other Indications
  • 5.2. Europe Rare Endocrine Disease Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Biologics
      • 5.2.1.2. Organic Compounds
  • 5.3. Europe Rare Endocrine Disease Treatment Market Outlook, by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Injectables
      • 5.3.1.2. Oral
      • 5.3.1.3. Others
  • 5.4. Europe Rare Endocrine Disease Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Hospital Pharmacies
      • 5.4.1.2. Retail Pharmacies
      • 5.4.1.3. Online Pharmacies
  • 5.5. Europe Rare Endocrine Disease Treatment Market Outlook, by Country, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 5.5.1. Key Highlights
      • 5.5.1.1. Germany Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.2. Germany Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.3. Germany Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.4. Germany Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.5. U.K. Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.6. U.K. Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.7. U.K. Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.8. U.K. Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.9. France Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.10. France Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.11. France Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.12. France Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.13. Italy Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.14. Italy Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.15. Italy Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.16. Italy Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.17. Turkey Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.18. Turkey Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.19. Turkey Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.20. Turkey Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.21. Russia Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.22. Russia Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.23. Russia Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.24. Russia Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.25. Rest of Europe Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.26. Rest of Europe Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.27. Rest of Europe Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 5.5.1.28. Rest of Europe Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Rare Endocrine Disease Treatment Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Rare Endocrine Disease Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Acromegaly
      • 6.1.1.2. Central Diabetes Insipidus
      • 6.1.1.3. Ahumada-Del Castillo Syndrome
      • 6.1.1.4. Hypoparathyroidism
      • 6.1.1.5. Other Indications
  • 6.2. Asia Pacific Rare Endocrine Disease Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Biologics
      • 6.2.1.2. Organic Compounds
  • 6.3. Asia Pacific Rare Endocrine Disease Treatment Market Outlook, by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Injectables
      • 6.3.1.2. Oral
      • 6.3.1.3. Others
  • 6.4. Asia Pacific Rare Endocrine Disease Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. Hospital Pharmacies
      • 6.4.1.2. Retail Pharmacies
      • 6.4.1.3. Online Pharmacies
  • 6.5. Asia Pacific Rare Endocrine Disease Treatment Market Outlook, by Country, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 6.5.1. Key Highlights
      • 6.5.1.1. China Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.2. China Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.3. China Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.4. China Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.5. Japan Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.6. Japan Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.7. Japan Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.8. Japan Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.9. South Korea Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.10. South Korea Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.11. South Korea Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.12. South Korea Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.13. India Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.14. India Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.15. India Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.16. India Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.17. Southeast Asia Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.18. Southeast Asia Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.19. Southeast Asia Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.20. Southeast Asia Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.21. Rest of Asia Pacific Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.22. Rest of Asia Pacific Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.23. Rest of Asia Pacific Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 6.5.1.24. Rest of Asia Pacific Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Rare Endocrine Disease Treatment Market Outlook, 2018 - 2031

  • 7.1. Latin America Rare Endocrine Disease Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Acromegaly
      • 7.1.1.2. Central Diabetes Insipidus
      • 7.1.1.3. Ahumada-Del Castillo Syndrome
      • 7.1.1.4. Hypoparathyroidism
      • 7.1.1.5. Other Indications
  • 7.2. Latin America Rare Endocrine Disease Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Biologics
      • 7.2.1.2. Organic Compounds
  • 7.3. Latin America Rare Endocrine Disease Treatment Market Outlook, by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Injectables
      • 7.3.1.2. Oral
      • 7.3.1.3. Others
  • 7.4. Latin America Rare Endocrine Disease Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Hospital Pharmacies
      • 7.4.1.2. Retail Pharmacies
      • 7.4.1.3. Online Pharmacies
  • 7.5. Latin America Rare Endocrine Disease Treatment Market Outlook, by Country, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 7.5.1. Key Highlights
      • 7.5.1.1. Brazil Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 7.5.1.2. Brazil Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 7.5.1.3. Brazil Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 7.5.1.4. Brazil Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 7.5.1.5. Mexico Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 7.5.1.6. Mexico Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 7.5.1.7. Mexico Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 7.5.1.8. Mexico Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 7.5.1.9. Argentina Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 7.5.1.10. Argentina Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 7.5.1.11. Argentina Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 7.5.1.12. Argentina Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 7.5.1.13. Rest of Latin America Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 7.5.1.14. Rest of Latin America Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 7.5.1.15. Rest of Latin America Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 7.5.1.16. Rest of Latin America Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Rare Endocrine Disease Treatment Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Rare Endocrine Disease Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Acromegaly
      • 8.1.1.2. Central Diabetes Insipidus
      • 8.1.1.3. Ahumada-Del Castillo Syndrome
      • 8.1.1.4. Hypoparathyroidism
      • 8.1.1.5. Other Indications
  • 8.2. Middle East & Africa Rare Endocrine Disease Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Biologics
      • 8.2.1.2. Organic Compounds
  • 8.3. Middle East & Africa Rare Endocrine Disease Treatment Market Outlook, by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Injectables
      • 8.3.1.2. Oral
      • 8.3.1.3. Others
  • 8.4. Middle East & Africa Rare Endocrine Disease Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. Hospital Pharmacies
      • 8.4.1.2. Retail Pharmacies
      • 8.4.1.3. Online Pharmacies
  • 8.5. Middle East & Africa Rare Endocrine Disease Treatment Market Outlook, by Country, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 8.5.1. Key Highlights
      • 8.5.1.1. GCC Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.2. GCC Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.3. GCC Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.4. GCC Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.5. South Africa Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.6. South Africa Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.7. South Africa Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.8. South Africa Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.9. Egypt Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.10. Egypt Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.11. Egypt Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.12. Egypt Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.13. Nigeria Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.14. Nigeria Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.15. Nigeria Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.16. Nigeria Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.17. Rest of Middle East & Africa Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.18. Rest of Middle East & Africa Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.19. Rest of Middle East & Africa Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
      • 8.5.1.20. Rest of Middle East & Africa Rare Endocrine Disease Treatment Market by Indication, Value (US$ Mn) and Volume (Tons), 2018 - 2031
    • 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. by Mode of Administration vs by Drug Type Heatmap
  • 9.2. Manufacturer vs by Drug Type Heatmap
  • 9.3. Company Market Share Analysis, 2023
  • 9.4. Competitive Dashboard
  • 9.5. Company Profiles
    • 9.5.1. Novartis
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Product Portfolio
      • 9.5.1.3. Financial Overview
      • 9.5.1.4. Business Strategies and Development
    • 9.5.2. Ipsen
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Product Portfolio
      • 9.5.2.3. Financial Overview
      • 9.5.2.4. Business Strategies and Development
    • 9.5.3. Pfizer, Inc
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Product Portfolio
      • 9.5.3.3. Financial Overview
      • 9.5.3.4. Business Strategies and Development
    • 9.5.4. Teva
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Product Portfolio
      • 9.5.4.3. Financial Overview
      • 9.5.4.4. Business Strategies and Development
    • 9.5.5. EMD serono
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Product Portfolio
      • 9.5.5.3. Financial Overview
      • 9.5.5.4. Business Strategies and Development
    • 9.5.6. Novo Nordisk
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Product Portfolio
      • 9.5.6.3. Financial Overview
      • 9.5.6.4. Business Strategies and Development
    • 9.5.7. Eli Lilly
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Product Portfolio
      • 9.5.7.3. Financial Overview
      • 9.5.7.4. Business Strategies and Development
    • 9.5.8. Shire
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Product Portfolio
      • 9.5.8.3. Financial Overview
      • 9.5.8.4. Business Strategies and Development
    • 9.5.9. Amgen, Inc
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Product Portfolio
      • 9.5.9.3. Financial Overview
      • 9.5.9.4. Business Strategies and Development
    • 9.5.10. Corcept Therapeutics
      • 9.5.10.1. Company Overview
      • 9.5.10.2. Product Portfolio
      • 9.5.10.3. Financial Overview
      • 9.5.10.4. Business Strategies and Development
    • 9.5.11. Novelion Therapeutics
      • 9.5.11.1. Company Overview
      • 9.5.11.2. Product Portfolio
      • 9.5.11.3. Financial Overview
      • 9.5.11.4. Business Strategies and Development

9.5.12.

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations